Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 5Triple Negative Breast Neoplasms 4Lung Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Ovarian Neoplasms 1Neuroendocrine Tumors 1Lymphoma, Non-Hodgkin 1Lymphoma 1HER2-negative Breast Cancer 1Gastric Adenocarcinoma 1Carcinoma, Small Cell 1Carcinoma, Ovarian Epithelial 1

Interventions

Cyclophosphamide 241Rituximab 223Etoposide 138Filgrastim 113Vincristine 112Doxorubicin 104Prednisone 90Cytarabine 90Methotrexate 79fludarabine phosphate 77Radiotherapy 76Peripheral Blood Stem Cell Transplantation 71Melphalan 71Busulfan 60Tacrolimus 48Dexamethasone 48Mycophenolic Acid 46Carmustine 46Granulocyte Colony-Stimulating Factor 44fludarabine 43Antilymphocyte Serum 40Ifosfamide 38sargramostim 34Whole-Body Irradiation 34Cyclosporine 33Bortezomib 32Gemcitabine 30Methylprednisolone 27Bendamustine Hydrochloride 27Lenalidomide 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoma × taxane × Clear all
NCT00044551 2013-10-14

Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma

Bayer

Phase 2 Completed
29 enrolled
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡